Transparency
We communicate clearly, consistently and responsibly, providing stakeholders with timely and balanced information on our progress, challenges and outcomes.
Our development model: From opportunity to patient impact
Five stages take a proven molecule from a scientific hunch to a treatment in a patient's hands.
We look for molecules with real scientific rationale behind them and a disease with no good answer. Starting from a compound already proven safe in people means the question is efficacy, not whether it can be given to a patient at all.
Preclinical and early clinical work establishes whether the rationale survives contact with data. This is the stage that decides whether a programme is worth a late-stage trial, and the stage where a disciplined company says no.
Randomised, double-blind, placebo-controlled trials run to a pre-agreed endpoint. Our lead programme, PARA_OA_012, recruited 538 participants across 65 sites in four countries against a 466 target.
We are a development company, not a global sales force. Partnerships with organisations that already have manufacturing, regulatory and commercial reach are how a treatment gets from a positive result to a patient.
Paradigm’s commercialisation strategy is supported by an established pharmaceutical manufacturing and supply chain. iPPS can be manufactured at commercial scale through an established source with a proven regulatory track record, avoiding the need to develop an entirely new manufacturing process or supply network.
This provides a strong foundation for commercial readiness, with demonstrated scalability, manufacturing continuity and greater certainty of supply as the program progresses toward potential registration and launch.
Our partners
Working with established partners across development, manufacturing, regulatory strategy and translational research.
